However, this was assessed for the experiment arm with maintenance durvalumab comparison within our PLATFORM study as previously published. 12 Surveillance visits were every 28 days, and patients ...

Monitoring assessments for capecitabine were performed weekly during cycle 1, every 2 weeks during cycle 2, and at clinic appointments during cycle 3 and subsequent cycles. In patients receiving ...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CY ...